
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology Inc. is poised for significant growth, with anticipated launch sales of its candidate, cretostimogene grenadenorepvec, beginning in 2026 and projected to reach approximately $2.6 billion by 2034, highlighting strong market potential driven by premium pricing strategies. The therapy addresses a critical unmet need for innovative treatments that could lower disease recurrence and enhance patient quality of life, suggesting a favorable reception among healthcare professionals and patients. Additionally, the promising clinical data supporting Creto’s efficacy and durability, alongside regulatory fast-tracking, underscores the company’s readiness for commercialization and positions it competitively in the expanding non-muscle invasive bladder cancer market.
Bears say
CG Oncology's stock outlook appears negative due to several significant risks associated with its clinical trials and overall market competitiveness. The potential for negative trial results, coupled with slower-than-expected enrollment and regulatory challenges, could hinder the timely commercialization of its bladder cancer therapies, thereby limiting market potential. Additionally, concerns regarding inadequate differentiation from existing therapies, such as Zaltrap's comparison to Avastin, raise questions about payer reimbursement sustainability, further compounding the challenges for CG Oncology's financial performance.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares